News archive
Showing 785 results
November 2015
-
Media Release
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will be… -
Media Release
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
-
Media Release
Novartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
Following a heart failure hospitalization, 44% fewer patients treated with Entresto were readmitted for heart failure, and 36% fewer patients were readmitted for any cause, within 30 days compared to… -
Media Release
Novartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
-
Media Release
Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
- 104 Week sub-analysis data from the Cosentyx Phase III FUTURE 1 trial in patients with psoriatic arthritis (PsA) presented at ACR 2015(1,2)- Patients receiving Cosentyx through 104 weeks maintained… -
Media Release
Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
- 104 Week sub-analysis data from the Cosentyx Phase III Measure 1 study in patients with ankylosing spondylitis (AS) presented at ACR 2015(1,2)- Two-year x-ray data from observational sub-analysis… -
Media Release
Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
-
Media Release
Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
October 2015
-
Media Release
FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
- Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and… -
Media Release
FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
-
Media Release
Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
As part of Q3 Earnings, Novartis announced that it reached a settlement in principle in the suit related to the Company's interactions with specialty pharmacies. Some media coverage did not…